French 
English 
Dutch Flow chemistry from drug discovery to commercial production
This page provides an overview of the major application areas where flow chemistry is used in pharmaceutical R&D.
A standard tool used across the full span of pharmaceutical R&D
Flow chemistry has progressed from a specialized academic technique into a standard tool used across the full span of pharmaceutical research and development. It is used from early medicinal chemistry exploration through process development and, under the regulatory framework established by ICH Q13, into commercial continuous manufacturing.
This page provides an overview of the major application areas where flow chemistry is used in pharmaceutical R&D, and outlines how the technique supports the broader goals of accelerating development timelines, expanding access to hazardous chemistry, and enabling more direct translation from laboratory-scale synthesis to production-scale manufacturing.
Medicinal chemistry and structure-activity relationship screening
In early drug discovery, medicinal chemists synthesize large numbers of structural analogues to explore structure-activity relationships, commonly abbreviated SAR, and flow chemistry platforms are increasingly used to accelerate this exploration. Laboratory flow systems, including Syrris Asia platform, allow rapid variation of reaction parameters, including temperature, residence time and reagent stoichiometry, using microliter to milliliter quantities of material per experiment. This is particularly valuable during SAR exploration, where starting material availability is often limited to whatever quantity was produced in a previous synthetic step, and where the same reaction, run under many slightly different conditions, needs to be optimized quickly without consuming large amounts of scarce intermediate.
The ability to rapidly reconfigure flow rate, temperature and residence time between experiments, often under automated or semi-automated control, allows medicinal chemistry teams to generate optimization data across a wide condition space in a fraction of the time required to run equivalent batch experiments sequentially, each requiring separate vessel setup, heating and cooling cycles.
Access to hazardous chemistry
One of the most significant contributions of flow chemistry to pharmaceutical R&D is expanding practical access to reactions that are hazardous, and therefore historically avoided, minimized, or outsourced to specialized facilities. Diazomethane chemistry is a frequently cited example: diazomethane is both toxic and explosive, and traditional batch handling requires generating it in a dedicated apparatus, then using it immediately in small quantities under carefully controlled conditions. Flow generation and telescoped consumption of diazomethane within a connected reactor system avoids ever isolating or accumulating a significant quantity of the compound, since it is generated and consumed continuously within a small reactor volume.
Similarly, azide chemistry, historically approached cautiously in batch due to the explosive potential of many azide compounds, particularly at elevated temperature or on evaporation to dryness, can be handled with reduced risk in flow, since the small standing inventory within the reactor limits the consequence of any unintended exotherm or decomposition event. Organolithium and other strong organometallic chemistry run at cryogenic temperature, traditionally requiring specialized cryogenic batch reactor infrastructure to maintain temperatures as low as -78° C across a large reaction volume, can often be run more practically in flow, since the high heat transfer rate of a microreactor or coiled reactor allows tight temperature control to be maintained even as reagents are added and react, without requiring the same scale of cryogenic cooling infrastructure needed to maintain an equivalent batch volume at low temperature.
This expanded access to hazardous chemistry is significant for pharmaceutical R&D because it broadens the practical synthetic toolkit available to process chemists, allowing routes that would otherwise be deprioritized due to batch handling hazards to be considered on their chemical potential.
Multistep telescoped synthesis
Flow chemistry’s capacity for telescoping, meaning the direct connection of sequential reaction steps without isolating intermediates, is a significant application area in pharmaceutical process development, particularly for synthetic routes involving unstable intermediates. When an intermediate compound is prone to degradation, decomposition, or further unwanted reaction if stored or handled outside the immediate reaction environment, telescoping allows that intermediate to be generated and immediately consumed within a connected flow system.
Telescoped flow sequences in pharmaceutical development have been applied across a range of multistep transformations, including sequences combining an organometallic addition step with a subsequent quench and functionalization step, and sequences combining a hazardous intermediate generation step, such as diazonium salt formation, with immediate downstream consumption. Beyond the stability benefits, telescoping reduces overall processing time across a multistep sequence by eliminating the workup and isolation steps that would otherwise separate each stage, and can improve overall sequence yield by avoiding the incremental material losses that accumulate each time an intermediate is isolated and handled separately.
Process development and scale-up translation
Flow chemistry supports a more direct and predictable translation from laboratory-scale synthesis to pilot and production-scale manufacturing compared to batch processes, primarily because of the numbering-up scale-up strategy available in flow. When a reaction is developed and validated using a specific microreactor or coiled reactor geometry at laboratory scale, that same reactor geometry can, in principle, be replicated in parallel at larger scale, preserving the mixing, heat transfer and residence time distribution characteristics established during laboratory development. This reduces the re-optimization burden typically required when translating a batch process from laboratory glassware to pilot-scale and production-scale vessels, where changes in surface-area-to-volume ratio and mixing behaviour with increasing vessel size often necessitate significant additional development work.
This more direct scale-up translation is particularly valuable in pharmaceutical development timelines, where the ability to move quickly and predictably from initial process development to material supply for toxicology studies, clinical trials, and eventually commercial manufacturing can materially affect overall program timelines.
Continuous manufacturing under ICH Q13
For late-stage development and commercial manufacturing, flow chemistry serves as a core enabling technology for continuous manufacturing, as defined and regulated under ICH Q13, the international guideline finalized in November 2022 addressing scientific and regulatory considerations for the development, implementation, operation and lifecycle management of continuous manufacturing of drug substances and drug products. The European Medicines Agency adopted this guideline under reference EMA/CHMP/ICH/427817/2021, with a legal effective date of 10 July 2023, and the guideline applies both to new products developed directly using continuous manufacturing and to the conversion of existing batch-manufactured products to continuous manufacturing processes.
ICH Q13 establishes expectations for several elements central to continuous manufacturing built on flow chemistry platforms, including a defined control strategy capable of ensuring consistent product quality throughout continuous operation, characterization of residence time distribution as a critical parameter for understanding material flow and identifying sources of process variability, material traceability approaches that allow specific portions of continuously produced material to be tracked and, if necessary, diverted or dispositioned separately, and defined approaches for managing transient process disturbances without requiring the entire production campaign to be halted or discarded, in contrast to batch manufacturing, where a deviation typically affects a single, discretely bounded batch.
Academic and industry collaboration in flow technology development
The adoption of flow chemistry across pharmaceutical R&D has been supported by significant collaborative development work between academic institutions and pharmaceutical companies, aimed at building the specialized engineering and process chemistry expertise required to design, validate and operate continuous flow manufacturing systems.
This collaborative model reflects the recognition that flow chemistry implementation requires knowledge spanning traditional synthetic and process chemistry, chemical engineering principles related to reactor design and mass and heat transfer, and increasingly, process analytical technology and data systems supporting real-time monitoring and control. As continuous manufacturing adoption continues to expand under the ICH Q13 framework, this cross-disciplinary expertise is becoming an increasingly standard component of pharmaceutical process development capability.
Discuss your application with our Xperts
Our Xperts are happy to discuss your application and help you find the right solution.
FAQ
What is flow chemistry used for in pharmaceutical R&D?
Flow chemistry is used throughout pharmaceutical research and development, including medicinal chemistry, route scouting, process optimization, hazardous chemistry, multistep synthesis, scale-up, and continuous manufacturing. It helps accelerate development timelines while improving process control and safety.
How does flow chemistry accelerate pharmaceutical drug discovery?
Flow chemistry allows medicinal chemists to rapidly screen reaction conditions by adjusting temperature, residence time, and reagent ratios using very small quantities of material. This speeds up structure-activity relationship (SAR) studies and reaction optimization.
Why is flow chemistry valuable for medicinal chemistry?
Medicinal chemistry often requires the synthesis of many analogues from limited quantities of starting materials. Flow chemistry enables efficient experimentation using microliter to milliliter quantities, reducing material consumption while increasing experimental throughput.
What is SAR screening in drug discovery?
Structure-activity relationship (SAR) screening is the process of synthesizing and testing related molecules to understand how structural changes affect biological activity. Flow chemistry helps accelerate SAR studies by allowing rapid reaction optimization.
How does flow chemistry improve pharmaceutical process development?
Flow chemistry provides precise control over reaction conditions, improves reproducibility, facilitates automation, and enables direct translation from laboratory optimization to larger-scale production.
How does flow chemistry improve the safety of diazomethane reactions?
Flow systems can generate diazomethane and consume it immediately in a connected process. This prevents the accumulation or storage of significant quantities of a highly toxic and explosive intermediate.
Why is flow chemistry useful for azide chemistry?
Azides can present explosion risks during batch handling. Flow chemistry minimizes these risks because only a small quantity of azide-containing material is present inside the reactor at any moment.
What advantages does flow chemistry offer for organolithium reactions?
Flow reactors provide excellent heat transfer and precise temperature control, making it easier to perform highly reactive organolithium chemistry under cryogenic conditions.
What is ICH Q13?
ICH Q13 is the international guideline that provides scientific and regulatory guidance for continuous manufacturing of pharmaceutical drug substances and drug products.
Why is ICH Q13 important for flow chemistry?
ICH Q13 establishes expectations for process control, residence time distribution, traceability, quality assurance, and lifecycle management of continuous manufacturing systems.
What pharmaceutical applications benefit most from flow chemistry?
Medicinal chemistry, SAR screening, hazardous chemistry, multistep synthesis, process intensification, scale-up, continuous manufacturing, and advanced process development all benefit significantly from flow chemistry.